Can homeopathic verum and placebo globules be distinguished by UV spectroscopy?

Purpose: Homeopathic preparations are used in homeopathy and anthroposophically extended medicine. Previous studies described differences in UV transmission between homeopathic preparations of CuSO4 and controls. The aim of the present study was to investigate whether statistically significant differences can be found between homeopathic verum and placebo globules by UV spectroscopy. Methods: Verum (aconitum 30c, calcium carbonate/quercus e cortice) and placebo globules used in two previous clinical trials were dissolved in distilled water at 10mg/ml 20-23h prior to the measurements. Absorbance was measured at 190 – 340nm with a Shimadzu UV-1800 double beam spectrophotometer. Duplicates of each sample were measured in a randomized order 4 times on each of the 5 measurement days. To correct for differences between measurement days, average absorbance of all samples on one day was deduced from absorbance of the individual samples. The Kruskal-Wallis test was used to determine group differences between the samples, and finally the coding of the samples was revealed. Results: First analysis showed significant differences (p≤0.05) in average UV absorbance at 200 – 290nm between the samples and a tendency of a correlation (p≤0.1) between absorbance and globule weight. More results will be presented at the conference. Conclusion: Since the absorbance of the samples at the wavelengths between 200 and 290nm was small, a number of aspects had to be considered and should be corrected for if they are present when performing UV spectroscopy on homeopathic globules: 1. Exact weighing of the globules. 2. Measurement error of the spectrophotometer at small absorbances. 3. Drift of the spectrophotometer during a measurement day. 4. Differences between measurement days. The question remains what caused the differences in absorbance found in these experiments: the use of the original material for the production of the verum globules, differences in the production of verum and placebo globules, or other context factors.

IL-9 and its receptor are predominantly involved in the pathogenesis of UC.

OBJECTIVE Several pathogenic roles attributed over the past two decades to either T helper (Th)1 or Th2 cells are increasingly becoming associated with interleukin (IL)-17 and most recently IL-9 signalling. However, the implication of IL-9 in IBD has not been addressed so far. DESIGN We investigated the expression of IL-9 and IL-9R by using peripheral blood, biopsies and surgical samples. We addressed the functional role of IL-9 signalling by analysis of downstream effector proteins. Using Caco-2 cell monolayers we followed the effect of IL-9 on wound healing. RESULTS IL-9 mRNA expression was significantly increased in inflamed samples from patients with UC as compared with controls. CD3(+) T cells were major IL-9-expressing cells and some polymorphonuclear leucocytes (PMN) also expressed IL-9. IL-9 was co-localised with the key Th9 transcription factors interferon regulatory factor 4 and PU.1. Systemically, IL-9 was abundantly produced by activated peripheral blood lymphocytes, whereas its receptor was overexpressed on gut resident and circulating PMN. IL-9 stimulation of the latter induced IL-8 production in a dose-dependent manner and rendered PMN resistant to apoptosis suggesting a functional role for IL-9R signalling in the propagation of gut inflammation. Furthermore, IL-9R was overexpressed on gut epithelial cells and IL-9 induced STAT5 activation in these cells. Moreover, IL-9 inhibited the growth of Caco-2 epithelial cell monolayers in wound healing experiments. CONCLUSIONS Our results provide evidence that IL-9 is predominantly involved in the pathogenesis of UC suggesting that targeting IL-9 might become a therapeutic option for patients with UC.

A quantitative reverse-transcriptase PCR assay for the assessment of drug activities against intracellular Theileria annulata schizonts.

Intracellular schizonts of the apicomplexans Theileria annulata and Theileria parva immortalize bovine leucocytes thereby causing fatal immunoproliferative diseases. Buparvaquone, a hydroxynaphthoquinone related to parvaquone, is the only drug available against Theileria. The drug is only effective at the onset of infection and emerging resistance underlines the need for identifying alternative compounds. Current drug assays employ monitoring of proliferation of infected cells, with apoptosis of the infected host cell as a read-out, but it is often unclear whether active compounds directly impair the viability of the parasite or primarily induce host cell death. We here report on the development of a quantitative reverse transcriptase real time PCR method based on two Theileria genes, tasp and tap104, which are both expressed in schizonts. Upon in vitro treatment of T. annulata infected bovine monocytes with buparvaquone, TaSP and Tap104 mRNA expression levels significantly decreased in relation to host cell actin already within 4 h of drug exposure, while significant differences in host cell proliferation were detectable only after 48-72 h. TEM revealed marked alterations of the schizont ultrastructure already after 2 h of buparvaquone treatment, while the host cell remained unaffected. Expression of TaSP and Tap104 proteins showed a marked decrease only after 24 h. Therefore, the analysis of expression levels of mRNA coding for TaSP and Tap104 allows to directly measuring impairment of parasite viability. We subsequently applied this method using a series of compounds affecting different targets in other apicomplexan parasites, and show that monitoring of TaSP- and Tap104 mRNA levels constitutes a suitable tool for anti-theilerial drug development.